ISSN: 2167-7700
Paola Cappello
Italy
Commentary
Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic
Approach in Pancreatic Cancer
Author(s): Moitza Principe, Paola Cappello and Francesco Novelli
Moitza Principe, Paola Cappello and Francesco Novelli
Background: We aimed to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE), a combination of raltitrexed, oxaliplatin, and epirubicin, for unresectable hepatocellular carcinoma (HCC). Methods: We enrolled 163 patients in this single-center, randomized, controlled trial comparing TACE with epirubicin and oxaliplatin (control group; 83 patients) to TACE with raltitrexed, epirubicin, and oxaliplatin (raltitrexed group; 80 patients).The primary endpoint was overall survival(OS);secondary endpoints included progression-free survival(PFS),tumor response and adverse events. Results: The median progression-free survival (mPFS) and overall survival (mOS) were similar (mPFS: 4.3 vs. 4.6 months, P = 0.201; mOS: 9.6 vs. 9.8 months, P = 0.698, respectively). The disease control rates for the control and raltitrexed groups were 57.8% and 63.8%, respectively, and did.. View More»
DOI:
10.4172/2167-7700.1000188